Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E Future Growth
Future criteria checks 5/6
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E is forecast to grow earnings and revenue by 27.1% and 17.3% per annum respectively. EPS is expected to grow by 26% per annum. Return on equity is forecast to be 22.6% in 3 years.
Key information
27.1%
Earnings growth rate
26.0%
EPS growth rate
Pharmaceuticals earnings growth | 17.8% |
Revenue growth rate | 17.3% |
Future return on equity | 22.6% |
Analyst coverage | Good |
Last updated | 15 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,932 | 716 | 248 | 522 | 3 |
12/31/2025 | 3,213 | 485 | 182 | 433 | 6 |
12/31/2024 | 2,918 | 361 | 177 | 349 | 2 |
12/31/2023 | 1,922 | 223 | -298 | -44 | N/A |
9/30/2023 | 1,779 | 226 | -424 | -199 | N/A |
6/30/2023 | 1,615 | 221 | -317 | -101 | N/A |
3/31/2023 | 1,533 | 224 | -169 | -42 | N/A |
12/31/2022 | 1,484 | 229 | -99 | 29 | N/A |
9/30/2022 | 1,487 | 254 | 22 | 160 | N/A |
6/30/2022 | 1,420 | 229 | -94 | 234 | N/A |
3/31/2022 | 1,321 | 207 | 27 | 268 | N/A |
12/31/2021 | 1,246 | 166 | 3 | 241 | N/A |
9/30/2021 | 1,140 | 136 | -69 | 173 | N/A |
6/30/2021 | 1,060 | 115 | -5 | 87 | N/A |
3/31/2021 | 1,010 | 106 | -185 | -39 | N/A |
12/31/2020 | 960 | 97 | -365 | -164 | N/A |
9/30/2020 | 947 | 119 | -350 | -162 | N/A |
6/30/2020 | 947 | 105 | -248 | -83 | N/A |
3/31/2020 | 921 | 94 | -143 | -15 | N/A |
12/31/2019 | 894 | 82 | -38 | 53 | N/A |
9/30/2019 | 853 | 85 | -55 | 215 | N/A |
6/30/2019 | 815 | 90 | -185 | 82 | N/A |
3/31/2019 | 810 | 110 | -216 | 42 | N/A |
12/31/2018 | 806 | 129 | -248 | 3 | N/A |
12/31/2017 | 628 | 89 | -59 | -17 | N/A |
12/31/2016 | 382 | 27 | N/A | 25 | N/A |
12/31/2015 | 278 | 10 | N/A | 25 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RMDA's forecast earnings growth (27.1% per year) is above the savings rate (14%).
Earnings vs Market: RMDA's earnings (27.1% per year) are forecast to grow faster than the EG market (15.2% per year).
High Growth Earnings: RMDA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RMDA's revenue (17.3% per year) is forecast to grow faster than the EG market (14.3% per year).
High Growth Revenue: RMDA's revenue (17.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RMDA's Return on Equity is forecast to be high in 3 years time (22.6%)